Accelsiors is a full-service clinical development partner that supports emerging biotech companies through early-phase clinical development — from preclinical-to-clinical transition strategy, through study design and regulatory preparation, to first-in-human execution and early proof-of-concept studies. We work with closely collaborating early-phase clinical research environments in Europe to match each programme to the right study setting.
We support first-in-human (FIH) studies, single and multiple ascending dose (SAD/MAD) studies, PK/PD and biomarker-intensive studies, dose escalation studies, early proof-of-mechanism and proof-of-concept studies, food effect studies, and early Phase II dose-ranging studies. We support both healthy volunteer and patient-based early-phase pathways, as well as pediatric early-phase studies.
Yes. Accelsiors supports pediatric early-phase clinical development through two pathways: programmes that move directly from nonclinical development into pediatric first-in-human studies (for example, in inborn errors of metabolism or rare pediatric genetic disorders), and programmes that extrapolate from adult clinical data into pediatric populations. Our collaborating clinical research environments include hospital-integrated settings with pediatric clinical departments and investigators.
Study-setting fit is the alignment between what a study requires and what the clinical research environment can deliver. Not every early-phase study belongs in the same type of unit. A healthy volunteer SAD study has different operational needs than a patient-based proof-of-mechanism study with intensive biomarker sampling, or a pediatric dose-finding study in young children. Accelsiors helps sponsors match each programme to the setting that gives it the best chance of generating clean, interpretable, decision-grade data.
Accelsiors works with closely collaborating early-phase clinical research environments in Europe. These include hospital-integrated settings within tertiary healthcare institutions, providing access to both healthy volunteer and patient populations, specialist clinical departments (including pediatric departments), and hospital-grade infrastructure for safety monitoring and intensive PK/PD sampling.
Healthy volunteer studies are often used for initial safety, tolerability, and PK characterisation — particularly in first-in-human programmes. Patient-based early-phase studies are used when the mechanism, indication, or risk profile requires patient exposure from the outset — enabling early efficacy signal detection and pharmacodynamic assessment in the target population. Accelsiors supports both pathways and helps sponsors determine which approach best serves their programme.
Accelsiors embeds PK/PD analysis, pharmacometrics, modelling and simulation, and biomarker strategy into study design from the outset. Our teams design PK sampling strategies for robust parameter estimation, select and validate PD biomarker endpoints, use modelling and simulation to support dose escalation decisions and exposure-response predictions, and ensure that translational hypotheses from preclinical development are tested with clinical data.
Yes. Supporting the preclinical-to-clinical transition is one of Accelsiors’ core strengths. We help emerging biotech teams align package logic, dose rationale, translational readiness, biomarker strategy, operational buildability, and study-setting fit before those assumptions harden into delay or avoidable rework.
Accelsiors supports programmes requiring pediatric dose modelling, including population PK approaches, physiologically-based pharmacokinetic (PBPK) modelling, and maturation-based scaling for young populations. Biomarker strategies are re-designed for pediatric feasibility, accounting for sample volume constraints, assay sensitivity requirements, and the practical realities of specimen collection in young children.
Accelsiors is a full-service clinical development partner. Early-phase clinical development is one of our strongest areas, but our support extends through Phase II and beyond. Our early-phase work is designed to connect into the broader development pathway — whether that means continuing with Accelsiors or ensuring a structured handover to the next development partner.
You can schedule an early-phase discussion directly through our website. We will help you assess your options, match your study to the right setting, and build an execution plan that supports confident progression. You can also download our white paper, Bridging Gaps: 5 Strategies for a Seamless Preclinical-to-Clinical Transition, for a practical overview of the key readiness questions.
The Preclinical-to-Clinical Transition Pack is a short, practical readiness lens for emerging biotech teams preparing to move from preclinical development into first-in-human and early clinical execution. It helps teams pressure-test the assumptions most likely to create package weakness, startup fragility, poor study-setting fit, biomarker and PK/PD execution gaps, and avoidable rework. It is available as a free download or can be shared on request during a discussion with our team.
